학메디칼

비상장계속사업자

Hak Medical

강치현

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

학메디칼

Business Reg. No. 4018157326 · CEO 강치현

I.Investment Overview

Target학메디칼 (4018157326)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명학메디칼
영문명Hak Medical
대표자강치현
사업자등록번호4018157326
법인등록번호1358110270511
설립일2015.05.27

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW735.42021701.82022448.92023305.720243212025
영업이익100M KRW247.62021120.3202220.22023-28.820243.62025
순이익100M KRW196.6202180.6202223.82023-30.520240.62025
Item20252024202320222021
자산총계391.1억원407.3억원441.3억원436.1억원516.7억원
부채총계124.4억원136.3억원123.8억원132.4억원288.6억원
자본총계266.7억원271.1억원317.5억원303.7억원228.1억원
매출액321억원305.7억원448.9억원701.8억원735.4억원
영업이익3.6억원-28.8억원20.2억원120.3억원247.6억원
순이익6,437만원-30.5억원23.8억원80.6억원196.6억원

VI.Financial Ratios

FY2025 basis

1.11%

영업이익률

0.2%

순이익률

0.16%

ROA

0.24%

ROE

46.65%

부채비율

68.19%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

학메디칼 투심보고서 | Alpha Lenz